Printer Friendly

AS COSTLY NEW MIGRAINE DRUG HITS THE U.S. MARKET, CLINICAL INTEREST IS SURGING IN A LESS EXPENSIVE 50-YEAR OLD THERAPY

 EAST HANOVER, N.J. March 19 /PRNewswire/ -- On March 18, the price of a new injectable migraine drug was announced at a press conference in New York City.
 However, recent clinical observations are part of a trend pointing to positive similarities between the new drug, Imitrex, (sumatriptan succinate) Injection, and a 50-year-old migraine drug that is considerably less expensive. the 50-year old drug is DHE-45(R) (dihydroergotamine mesylate) Injection, USP, marketed by Sandoz Pharmaceuticals Corporation.
 DHE-45 is currently available as an injection. However, Sandoz is waiting for approval to market, in addition, a nasal spray formulation of DHE-45.
 A wave of clinical studies on DHE-45 led the agenda of the most recent annual scientific conference of the American Association for the Study of Headache.
 ----
 NOTE TO EDITORS: Leading headache authorities are available for commentary and background information.
 -0- 3/19/93
 /CONTACT: Matt Lindley or Jim Weinrebe of BBK, 617-734-4400, for Sandoz Pharmaceuticals/


CO: Sandoz Pharmaceuticals ST: New Jersey IN: MTC SU: PDT

TM -- NE003 -- 7800 03/19/93 09:58 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1993
Words:172
Previous Article:WINTHROP RESOURCES FILES REGISTRATION STATEMENT FOR SECONDARY OFFERING OF 1,500,000 SHARES
Next Article:LYNTON GROUP, INC. ANNOUNCES REVENUES & EARNINGS; DRAMATIC REDUCTION IN NET INCOME LOSS FOR FIRST QUARTER.
Topics:


Related Articles
STUDY POINTS TO NEW HOPE FOR MIGRAINE SUFFERERS IN 50-YEAR-OLD DRUG
'REDISCOVERED' 50-YEAR OLD MIGRAINE DRUG AND NEWLY APPROVED THERAPY OFFER NEW HOPE FOR RELIEF FROM HEADACHE PAIN
BUTORPHANOL TARTRATE NASAL SPRAY OFFERS CONVENIENT THERAPY FOR TREATING MIGRAINE PAIN
MIGRAINE NASAL SPRAY PROVIDES SAFE, EFFECTIVE RELIEF OF HEADACHE PAIN AND NAUSEA, CONCLUDES RECENT STUDY AT UNIVERSITY OF KANSAS MEDICAL CENTER
MIGRAINE NASAL SPRAY PROVIDES SAFE, EFFECTIVE RELIEF OF HEADACHE PAIN AND NAUSEA, CONCLUDES RECENT STUDY AT UNIVERSITY OF KANSAS MEDICAL CENTER
Glaxo Wellcome Inc. Receives Clearance to Market Imitrex(R) Nasal Spray in the U.S.
Glaxo Wellcome Inc. Receives Clearance to Market Amerge(TM) (Naratriptan Hydrochloride) Tablets in U.S.
NIH and American Biogenetic Sciences Embark on Research Collaboration Study Will Evaluate ABS' New Epilepsy Treatment
Synaptic Pharmaceutical and Lilly Announce Advancement of Migraine Compound Into Late Stage Clinical Trials
Ortho-McNeil Pharmaceutical, Inc. Announces Early Termination of FTC Review For Rights to AXERT(R) for Migraine Headaches.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters